Blood test predicts lung cancer 5 years early, WEHI study finds
Synopsis
Australian researchers have identified a 14-protein blood signature capable of flagging lung cancer risk more than five years before diagnosis — and it works in non-smokers too. Published in Cell and validated across 48,000 samples, this could fundamentally reshape who gets screened and when, moving prevention upstream of the tumour itself.
Key Takeaways
WEHI researchers published findings in Cell on 6 June identifying a blood-based early lung cancer marker.
A 14-protein signature predicted lung cancer risk within five years of diagnosis.
The study analysed over 48,000 blood samples and was validated across eight international datasets .
The signature works in non-smokers , expanding potential screening beyond current high-risk groups.
The marker reflects pre-tumour lung inflammation , not the tumour itself, suggesting a window for preventative intervention.
Lung cancer is the leading cause of cancer deaths globally; current screening misses many cases until late stages.
A newly identified 14-protein blood signature can predict lung cancer risk more than five years before diagnosis, according to a study published in the journal Cell by researchers at Australia's Walter and Eliza Hall Institute of Medical Research (WEHI). The findings, released on 6 June, could open a pathway to earlier prevention — even before a tumour develops.
What the Study Found
The research analysed over 48,000 blood samples, identifying a combination of 14 proteins whose presence in the bloodstream predicted lung cancer risk within a five-year window. The signature was validated across eight international datasets, including samples from non-smokers — a group largely excluded from current screening programmes.
Crucially, researchers noted that the signature does not originate from the tumour itself. Instead, it appears to reflect an altered inflammatory environment in the lungs that precedes cancer formation, pointing to a pre-disease phase in which preventative intervention may be feasible.
Why This Matters for Screening
Lung cancer remains the leading cause of cancer deaths globally. Existing screening programmes are largely restricted to older individuals with a significant smoking history, leaving a substantial portion of at-risk patients undetected until the disease reaches advanced, harder-to-treat stages.
This is the gap the new blood marker could help close. By identifying risk earlier and more broadly, clinicians could potentially direct preventative drugs toward patients before a diagnosis is ever made — a meaningful shift in the current care model.
What the Researchers Said
Clare Weeden, laboratory head at WEHI and a corresponding author on the paper, said the study could lead to 'more inclusive and effective screening approaches for people in Australia and across the world.' She conducted the core research during her tenure at the Francis Crick Institute in Britain.
'In doing so, these findings bring us closer to a future where early intervention is possible, even before the cancer has a chance to develop,' Weeden said.
Charlie Swanton, clinical research director at the Crick Institute, said the findings support a growing hypothesis that certain common age-related diseases share a 'common, presymptomatic state of inflammation.' He added that the signature could eventually help predict and prevent not just lung cancer but other lung diseases as well.
Broader Implications
The study's validation across multiple international cohorts strengthens its generalisability beyond any single population or geography. For India, where lung cancer incidence is rising and screening infrastructure remains limited, a blood-based early-detection tool could carry particular public health significance.
The next steps will likely involve clinical trials to determine whether the signature can guide real-world preventative treatment decisions — and whether acting on it measurably reduces cancer incidence.
Point of View
Which means a large share of lung cancer patients are invisible to the system until it is too late. A blood marker that works across risk profiles challenges that paradigm directly. The harder question is translation: from Cell paper to clinical protocol is a long road, and the history of promising cancer biomarkers is littered with findings that did not survive the journey to routine use. The inflammation-first framing is intellectually compelling, but it will need prospective intervention trials — not just predictive validation — before it changes how oncologists act.
NationPress
11 Aug 2026
Frequently Asked Questions
What is the blood signature identified in the WEHI lung cancer study?
It is a combination of 14 proteins detectable in a blood sample that was found to predict lung cancer risk more than five years before diagnosis. The signature was identified through analysis of over 48,000 blood samples and validated across eight international datasets.
Why is this lung cancer blood test significant?
Current lung cancer screening is largely limited to older, heavy smokers, leaving many at-risk individuals undetected until late stages. This blood marker works in non-smokers too, potentially enabling much earlier and broader preventative intervention.
Where does the 14-protein signature come from — the tumour?
No. Researchers found the signature does not originate from the tumour itself. It reflects an altered inflammatory environment in the lungs that precedes cancer, indicating a pre-disease phase where prevention may be possible.
Who conducted the research and where was it published?
The study was led by researchers at Australia's Walter and Eliza Hall Institute of Medical Research (WEHI), with key work conducted at the Francis Crick Institute in Britain. It was published in the peer-reviewed journal Cell on 6 June.
What are the next steps for this research?
Researchers and clinicians will need to conduct prospective clinical trials to determine whether acting on the blood signature — for instance, by administering preventative drugs — measurably reduces lung cancer incidence before the test can enter routine clinical use.
